Results 41 to 50 of about 1,923,383 (256)

The Chimeric Antigen Receptor Detection Toolkit

Frontiers in Immunology, 2020
Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from ...
Yifei Hu, Yifei Hu, Jun Huang
doaj   +1 more source

Unlocking the potential of Tregs: innovations in CAR technology

Frontiers in Molecular Biosciences, 2023
Regulatory T cells (Tregs) adoptive immunotherapy is emerging as a viable treatment option for both autoimmune and alloimmune diseases. However, numerous challenges remain, including limitations related to cell number, availability of target-specific ...
Christopher J. Requejo Cier, Nicolas Valentini, Caroline Lamarche   +2 more
doaj   +1 more source

Drug functional remapping: a new promise for tumor immunotherapy

Frontiers in Oncology
The research and development of new anti-cancer drugs face challenges such as high costs, lengthy development cycles, and limited data on side effects.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Ting Su, Ting Su, Ting Su, Ting Su, Jiexiong Wu, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Minghan Song, Minghan Song, Minghan Song, Canfeng He, Canfeng He, Canfeng He, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Yubin Yang, Yubin Yang, Size Chen, Size Chen, Size Chen, Size Chen   +27 more
doaj   +1 more source

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Science Translational Medicine, 2015
CAR T cells persist and sustain remissions in advanced chronic lymphocytic leukemia. CAR T cells for the long haul Immunotherapy is one of the most promising avenues of cancer therapy, with the potential to induce sustained remissions in patients with ...
D. Porter, W. Hwang, N. Frey, S. Lacey, P. Shaw, A. Loren, A. Bagg, K. Marcucci, Angela Shen, Vanessa E. Gonzalez, David E. Ambrose, S. Grupp, A. Chew, Zhaohui Zheng, M. Milone, B. Levine, J. Melenhorst, C. June   +17 more
semanticscholar   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Molecular Therapy, 2010
In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab (Herceptin).
R. Morgan, J. Yang, M. Kitano, M. Dudley, C. Laurencot, S. Rosenberg   +5 more
semanticscholar   +1 more source

Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia

, 2020
Dataset of the study “Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-cell Acute Lymphoblastic Leukemia”
Jiakui Zhang (8521494), Zhimin Zhai (8521391), Qianshan Tao (8521500), Furun An (8521383), Weiwei Zhu (8521515), Xiaotong Song (8521521), Hui Qin (8521517), Fan Wu (8521491), Yanjie Ruan (8521508), Yansheng Wang (8521518), Zhenqing Feng (8521520), Yuanyuan Shen (8521505), Huiping Wang (8521482), Qing Zhang (8521509), Yingwei Li (8521503), Ying Pan (8521512), Zhenyun Liu (8521488)   +16 more
core   +2 more sources

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells

Frontiers in Genetics, 2020
The term cancer stem cell (CSC) starts 25 years ago with the evidence that CSC is a subpopulation of tumor cells that have renewal ability and can differentiate into several distinct linages.
Rowa Y. Alhabbab
doaj   +1 more source

Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies

Science Translational Medicine, 2022
Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells showed exceptional successes in patients with refractory B cell malignancies. However, first-in-human studies in solid tumors revealed unique hurdles contributing to poor demonstration
Beatrice Greco, Valeria Malacarne, Federica De Girardi, G. Scotti, F. Manfredi, E. Angelino, Camilla Sirini, B. Camisa, Laura Falcone, M. Moresco, Katia Paolella, Mattia Di Bono, R. Norata, F. Sanvito, Silvia Arcangeli, C. Doglioni, F. Ciceri, C. Bonini, A. Graziani, A. Bondanza, M. Casucci   +20 more
semanticscholar   +1 more source